Damage to dopamine systems differs between parkinson's disease and alzheimer's disease with parkinsonism
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Parkinsonism occurs in approximately 35 to 40% of patients with Alzheimer's disease (AD) even with little or no neuronal degeneration in the substantia nigra, which in idiopathic Parkinson's disease (PD) results in the severe loss of striatal dopamine transporter sites. It is not known if there is a loss of striatal dopamine transporter sites in AD with coexistent parkinsonism (AD/parkinsonism). We quantified the pattern of these sites in the striatum and midbrain of patients with the clinical diagnosis of PD, AD, and AD/parkinsonism in comparison with a group of age‐matched control subjects. We also quantified the number of D2 receptors and the levels of tyrosine hydroxylase in the substantia nigra and ventral tegmental area of same groups. The results showed that in AD the loss of dopamine transporter sites was restricted to the nucleus accumbens. The loss of these sites in the AD/parkinsonism group was more extensive than in the AD group, with the most severe losses in the rostral caudate and putamen and least in the caudal caudate and putamen. While the PD group showed an equally severe reduction in numbers of sites, the caudal to rostral gradient of loss differed from that in the AD/parkinsonism group. The PD group also showed a marked loss of dopamine transporter sites, tyrosine hydroxylase, and D2 autoreceptors (located on dopamine neurons) in the substantia nigra and ventral tegmental area. In contrast, no reductions in dopamine transporter sites, tyrosine hydroxylase, and D2 autoreceptors were observed in the substantia nigra and ventral tegmental area of the AD or AD/parkinsonism groups. Thus, the loss of striatal dopamine transporter sites in AD/parkinsonism may be related to the clinical parkinsonian symptoms. However, the loss is not simply the result of neuronal degeneration in the substantia nigra, but must derive from other processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Loss of Dopamine Uptake Sites Labeled with [ 3 H]GBR-12935 in Alzheimer’s Disease
Allard, P., Alafuzoff, I., Carlsson, A., Eriksson, K., Ericson, E., Gottfries, C.-G., & Marcusson, J. O. (2008) · European Neurology · doi:10.1159/000117341 · Cited by 64
Cited by
Joel, D., & Weiner, I. (2000) · Neuroscience · doi:10.1016/s0306-4522(99)00575-8 · Cited by 614
Piggott, M. A., Marshall, E. F., Thomas, N., Lloyd, S., Court, J. A., Jaros, E., Burn, D., Johnson, M., Perry, R. H., McKeith, I. G., et al. (1999) · Brain · doi:10.1093/brain/122.8.1449 · Cited by 330
The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies
Seidel, K., Mahlke, J., Siswanto, S., Krüger, R., Heinsen, H., Auburger, G., Bouzrou, M., Grinberg, L. T., Wicht, H., Korf, H., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12168 · Cited by 306
“Is dopamine involved in Alzheimer's disease?â€
Martorana, A., & Koch, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00252 · Cited by 275
What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?
Tiraboschi, P., Salmon, D. P., Hansen, L. A., Hofstetter, R. C., Thal, L. J., & Corey-Bloom, J. (2006) · Brain · doi:10.1093/brain/awh725 · Cited by 272
Motor signs during the course of Alzheimer disease
Scarmeas, N., Hadjigeorgiou, G. M., Papadimitriou, A., Dubois, B., Sarazin, M., Brandt, J., Albert, M., Marder, K., Bell, K., Honig, L. S., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000138440.39918.0c · Cited by 256
Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis
Cummings, J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00183-4 · Cited by 238
“Patients with AD and parkinsonism also have been found to have a loss of dopamine transporter sites in the rostral caudate and putamen compared to AD patients without parkinsonism [28].”
BackgroundResultMethamphetamine: Effects on the brain, gut and immune system
Prakash, M. D., Tangalakis, K., Antonipillai, J., Stojanovska, L., Nurgali, K., & Apostolopoulos, V. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.009 · Cited by 219
Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer’s Disease
Guo, L., Tian, J., & Du, H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160702 · Cited by 211
“A previous study has compared the difference of dopaminergic system deficits in PD, AD, and AD with parkinsonism and found that although all of them have loss of presynaptic dopamine receptor D2 (DRD2) and decreased levels of tyrosine hydroxylase, these three groups demonstrated distinct patterns of lesions sites, whi…”
Motor signs predict poor outcomes in Alzheimer disease
Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Hadjigeorgiou, G., Papadimitriou, A., Dubois, B., Sarazin, M., Wegesin, D., Marder, K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000162054.15428.e9 · Cited by 199
Donnemiller, E., Heilmann, J., Wenning, G. K., Berger, W., Decristoforo, C., Moncayo, R., Poewe, W., & Ransmayr, G. (1997) · European Journal of Nuclear Medicine · doi:10.1007/bf01728771 · Cited by 167
“The 123I-[3-CIT SPET findings revealed normal values for S/C 3 and S/C18, but significantly reduced delta values in DAT, which might reflect the mild to moderate degree of nigrostriatal degeneration observed post-mortem in DAT [4].”
BackgroundInfluentialLa Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E. C., Cutuli, D., Cauzzi, E., Marino, R., Viscomi, M. T., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102031 · Cited by 98
“deficits in mesocorticolimbic DA signalling (Allard et al., 1990; Costa et al., 2016; Gibb et al., 1989; Joyce et al., 1997; Kemppainen et al., 2003; Koch et al., 2014; Kumar and Patel, 2007; Murray et al., 1995; Rinne et al., 1986a, 1986b; Storga et al., 1996).”
Iaccarino, L., Sala, A., Caminiti, S. P., Presotto, L., Perani, D., & Initiative, F. T. A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190954 · Cited by 40
Metadata
- Authors
- Murray, A. M., Weihmueller, F. B., Marshall, J. F., Hurtig, H. I., Gottleib, G. L., & Joyce, J. N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1995-03
- Volume
- 37
- Issue
- 3
- Pages
- 300-312
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2152866161
- Cited by
- 136
- References
- 5
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.